A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Effect of Vandetanib on Cellular Markers of Proliferation and Apoptosis in Invasive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2019
Price : $35 *
At a glance
- Drugs Vandetanib (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- 23 Jan 2019 Status changed from suspended to discontinued.
- 31 Aug 2018 Biomarkers information updated
- 10 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.